A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.
et al., NCT04854928, NCT04854928, May 2022
RCT 33 patients up to 6 days from symptom onset, showing no significant difference in short-term viral load change with LTX-109.
|
viral load, 29.4% higher, relative load 1.29, p = 0.80, treatment 11, control 12, combined.
|
|
viral load, 6.4% lower, relative load 0.94, p = 0.96, treatment mean 233.1 (±893.6) n=11, control mean 218.1 (±584.6) n=12, deep nasal swab.
|
|
viral load, 93.3% higher, relative load 1.93, p = 0.65, treatment mean 96.19 (±452.8) n=11, control mean 185.9 (±491.6) n=12, anterior nasal swab.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lütken et al., 1 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Sweden, preprint, 1 author, trial NCT04854928 (history).
Contact: Christian.lutken@pharmaholdings.no, ryvoll@pharmaholdings.no.
